{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:08:59Z","timestamp":1787242139050,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Irritable bowel syndrome (IBS) is a common gastrointestinal condition. Some studies have shown the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS).\n                      <jats:italic>Weizmannia (Bacillus) coagulans<\/jats:italic>\n                      LMG S-31876 has been marketed as a dietary ingredient, but to date, its efficacy in diarrhea-predominant irritable bowel syndrome (IBS) condition has not been clinically elucidated. Thus, a double-blind placebo-controlled multi-centered trial was planned to evaluate the safety and efficacy of\n                      <jats:italic>Weizmannia (Bacillus) coagulans<\/jats:italic>\n                      LMG S-31876 in diarrhea-predominant IBS patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental design<\/jats:title>\n                    <jats:p>\n                      Study participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200950) diagnosed with IBS prominent symptoms that include abdominal pain and other GI-related symptoms were treated with ProBC Plus (2 billion CFU) along with a placebo capsule once daily for approximately 8\u2009weeks. Study participants were evaluated for the treatment success determined by the differences in stool consistency and frequency per day between the intervention and placebo groups over the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The vital signs and the biochemistry parameters were under the normal range; the other parameters showed a significant result as compared to the placebo during the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study depicts a significant decline in the clinical symptoms such as abdominal pain, bloating, diarrhea, and frequency of the stool as compared to the placebo. All the parameters such as hematology, lipid profile, and vital signs were in the normal range during the supplementation of ProBC Plus for a period of 8\u2009weeks. Furthermore, the study verified that\n                      <jats:italic>Weizmannia (Bacillus) coagulans<\/jats:italic>\n                      LMG S-31876 and its probiotic product ProBC Plus at a dose of 2 billion\/CFU\/day has a prominent action in the relief from the clinical symptoms of IBS-D. Therefore, the product is intended safe to utilize for IBS-related symptoms.\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>Clinical trial registration<\/jats:bold>\n                      : The clinical study has been registered with CTRI\/2023\/01\/048644 with\n                      <jats:ext-link>https:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=77708&amp;amp;EncHid=24313.96864&amp;amp;userName=CTRI\/2023\/01\/048644<\/jats:ext-link>\n                      [CTRI\/2023\/01\/048644].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2023.1310462","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:19:07Z","timestamp":1707124747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of Weizmannia (Bacillus) coagulans LMG S-31876 in treating IBS-diarrhea"],"prefix":"10.3389","volume":"10","author":[{"given":"Ranjith Kumar","family":"Kallur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenadh","family":"Madapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourish","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1053\/gast.1997.1122118","article-title":"American Gastroenterological Association medical position statement: irritable bowel syndrome","volume":"112","author":"Drossman","year":"1997","journal-title":"J Gastroenterol"},{"key":"ref2","article-title":"Diarrhea. 2022 Nov 21","volume-title":"StatPearls [Internet]","author":"Nemeth","year":"2023"},{"key":"ref3","first-page":"676","article-title":"Infectious diarrhea: IDSA updates guidelines for diagnosis and management","volume":"97","author":"Randel","year":"2018","journal-title":"Am Fam Physician"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study","volume":"160","author":"Sperber","year":"2021","journal-title":"J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1136\/gutjnl-2019-318536","article-title":"Novel concepts in the pathophysiology and treatment of functional dyspepsia","volume":"69","author":"Wauters","year":"2020","journal-title":"Gut"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/S0007114516004037","article-title":"Can probiotics modulate human disease by impacting intestinal barrier function?","volume":"117","author":"Bron","year":"2017","journal-title":"Br J Nutr"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6076","DOI":"10.3390\/molecules26196076","article-title":"Probiotics regulate gut microbiota: an effective method to improve immunity","volume":"26","author":"Wang","year":"2021","journal-title":"Molecules"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2050640618821804","article-title":"Prevalence and impact of self-reported irritable bowel symptoms in the general population","volume":"7","author":"Van den Houte","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0209205","DOI":"10.1371\/journal.pone.0209205","article-title":"Choosing an appropriate probiotic product for your patient: an evidence-based practical guide","volume":"13","author":"Sniffen","year":"2018","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2018.00124","article-title":"Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis","volume":"5","author":"LV","year":"2018","journal-title":"Front Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MPG.0000000000001081","article-title":"ESPGHAN working Group for Probiotics Prebiotics. Probiotics for the prevention of antibiotic-associated. Diarrhea in children","volume":"62","author":"Szajewska","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijsu.2020.04.063","article-title":"The efficacy and safety of probiotics for patients with constipation-predominant irritable bowel syndrome: a systematic review and meta-analysis based on seventeen randomized controlled trials","volume":"79","author":"Wen","year":"2020","journal-title":"Int J Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e24240","DOI":"10.7759\/cureus.24240","article-title":"Probiotics in irritable bowel syndrome: a review of their therapeutic role","volume":"14","author":"Kumar","year":"2022","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/nu11092048","article-title":"Probiotics in irritable bowel syndrome: an up-to-date systematic review","volume":"11","author":"Dale","year":"2019","journal-title":"Nutrients"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.21037\/apm-20-202","article-title":"Effects of exogenous probiotics on the gut microbiota and clinical outcomes in critically ill patients: a randomized controlled trial","volume":"10","author":"Wang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000510950","article-title":"Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study","volume":"39","author":"Barraza-Ortiz","year":"2021","journal-title":"Dig Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"853011","DOI":"10.36877\/pmmb.a0000069","article-title":"Role of low FODMAP diet and probiotics on gut microbiome in irritable bowel syndrome (IBS)","volume":"3","author":"Selvaraj","year":"2020","journal-title":"Prog Microb Mol Biol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3390\/life12091388","article-title":"In vitro evaluation of Weizmannia coagulans strain LMG S-31876 isolated from fermented rice for potential probiotic properties, safety assessment and technological properties","volume":"12","author":"Sreenadh","year":"2022","journal-title":"Life"},{"key":"ref22","first-page":"1","article-title":"Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy","volume":"52","author":"King","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S1359-6446(03)02746-6","article-title":"Using probiotics and prebiotics to improve gut health","volume":"8","author":"Tuohy","year":"2003","journal-title":"Drug Discov Today"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2146\/ajhp090168","article-title":"Probiotics","volume":"67","author":"Williams","year":"2010","journal-title":"Am J Health-Syst Pharm"},{"key":"ref25","article-title":"Guidelines for the evaluation of probiotics in food","volume-title":"Report of a joint FAO\/WHO working group on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada, April 30 and may 1, 2002","year":""},{"key":"ref26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/978-0-387-74087-4_17","article-title":"Probiotics, immunomodulation, and health benefits","volume":"606","author":"Gill","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"ref27","first-page":"808","article-title":"Probiotics as efficient immunopotentiators: translational role in cancer 1 prevention","volume":"138","author":"Shida","year":"2013","journal-title":"Indian J Med Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1208\/s12249-013-0027-1","article-title":"A review of the advancements in probiotic delivery: conventional vs. non-conventional formulations for intestinal flora supplementation","volume":"15","author":"Govender","year":"2014","journal-title":"Aaps Pharm SciTech"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"110428","DOI":"10.1016\/j.foodres.2021.110428","article-title":"Spore-forming Weizmannia (Bacillus) coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: a randomized controlled trial","volume":"146","author":"Kang","year":"2021","journal-title":"Food Res Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/jsfa.4367","article-title":"Probiotics and prebiotics -perspectives and challenges","volume":"91","author":"Figueroa-Gonz\u00e1lez","year":"2011","journal-title":"J Sci Food Agric"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1128\/IAI.73.6.3686-3692.2005","article-title":"Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock","volume":"73","author":"Luyer","year":"2005","journal-title":"Infect Immun"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3748\/wjg.14.2029","article-title":"Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults","volume":"14","author":"Kekkonen","year":"2008","journal-title":"World J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.phrs.2012.09.010","article-title":"The quest for probiotic effector molecules--unraveling strain specificity at the molecular level","volume":"69","author":"Lee","year":"2013","journal-title":"Pharmacol Res"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.micpath.2012.09.013","article-title":"Species and strain specificity of Lactobacillus probiotics effect on weight regulation","volume":"55","author":"Million","year":"2013","journal-title":"Microb Pathog"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3844\/ajisp.2013.103.109","article-title":"Physiological effects of a combination of cinnulin with probiotics","volume":"9","author":"Vaclav","year":"2013","journal-title":"Am J Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00228-018-2562-x","article-title":"A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Weizmannia (Bacillus) coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort","volume":"75","author":"Maity","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3810\/pgm.2009.03.1984","article-title":"Weizmannia (Bacillus) coagulans significantly improved abdominal pain and bloating in patients with IBS","volume":"121","author":"Hun","year":"2009","journal-title":"Postgrad Med J"},{"key":"ref39","first-page":"311","article-title":"Evaluation of anti-diarrhoeal activity of Bacillus coagulans MTCC 5856 and its effect on gastrointestinal motility in wistar rats","volume":"7","author":"Majeed","year":"2016","journal-title":"IJPBS"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrgastro.2014.40","article-title":"A role for the gut microbiota in IBS","volume":"11","author":"Collins","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1053\/gast.2002.34097","article-title":"A case for an immunological basis for irritable bowel syndrome","volume":"122","author":"Collins","year":"2002","journal-title":"J Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles","volume":"128","author":"O\u2019Mahony","year":"2005","journal-title":"J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2036.2007.03362.x","article-title":"Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial","volume":"26","author":"Guyonnet","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gut.2008.167270","article-title":"The efficacy of probiotics in the therapy of irritable bowel syndrome: a systematic review","volume":"59","author":"Moayyedi","year":"2008","journal-title":"Gut"},{"key":"ref45","article-title":"Process for enhancing the viable counts of lactic acid Bacteria and useful compositions thereof","author":"Majeed","year":"2015","journal-title":"US application No. 14839923; PCT\/US2015\/47608"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.3390\/jcm12144838","article-title":"The efficacy and safety of single-strain probiotic formulations containing Bifidobacterium lactis or Bacillus coagulans in adult patients with irritable bowel syndrome\u2014a randomized double-blind placebo-controlled three-arm interventional trial","volume":"12","author":"Skrzyd\u0142o-Radoma\u0144ska","year":"2023","journal-title":"J Clin Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"12210","DOI":"10.1038\/s41598-019-48554-x","article-title":"Randomized clinical trial: the effect of probiotic Bacillus coagulans unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults","volume":"9","author":"Madempudi","year":"2019","journal-title":"Sci Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e23641","DOI":"10.1097\/MD.0000000000023641","article-title":"Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: a prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT compliant]","volume":"100","author":"Gupta","year":"2021","journal-title":"Medicine"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1310462\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:19:12Z","timestamp":1707124752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2023.1310462\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":48,"alternative-id":["10.3389\/fnut.2023.1310462"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2023.1310462","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,5]]},"article-number":"1310462"}}